Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
413 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Malaria - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H2 2016, provides an overview of the Malaria (Infectious Disease) pipeline landscape. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 7, 62 and 29 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14, 46 and 41 molecules, respectively.Malaria. Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Malaria Overview 7 Therapeutics Development 8 Malaria - Therapeutics under Development by Companies 10 Malaria - Therapeutics under Investigation by Universities/Institutes 15 Malaria - Pipeline Products Glance 19 Malaria - Products under Development by Companies 22 Malaria - Products under Investigation by Universities/Institutes 29 Malaria - Companies Involved in Therapeutics Development 36 Malaria - Therapeutics Assessment 99 Drug Profiles 111 Malaria - Dormant Projects 362 Malaria - Discontinued Products 375 Malaria - Product Development Milestones 377 Appendix 390
List of Tables
Number of Products under Development for Malaria, H2 2016 30 Number of Products under Development for Malaria - Comparative Analysis, H2 2016 31 Number of Products under Development by Companies, H2 2016 32 Number of Products under Development by Companies, H2 2016 (Contd..1) 33 Number of Products under Development by Companies, H2 2016 (Contd..2) 34 Number of Products under Development by Companies, H2 2016 (Contd..3) 35 Number of Products under Development by Companies, H2 2016 (Contd..4) 36 Number of Products under Investigation by Universities/Institutes, H2 2016 37 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 38 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 39 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 40 Comparative Analysis by Late Stage Development, H2 2016 41 Comparative Analysis by Clinical Stage Development, H2 2016 42 Comparative Analysis by Early Stage Development, H2 2016 43 Products under Development by Companies, H2 2016 44 Products under Development by Companies, H2 2016 (Contd..1) 45 Products under Development by Companies, H2 2016 (Contd..2) 46 Products under Development by Companies, H2 2016 (Contd..3) 47 Products under Development by Companies, H2 2016 (Contd..4) 48 Products under Development by Companies, H2 2016 (Contd..5) 49 Products under Development by Companies, H2 2016 (Contd..6) 50 Products under Investigation by Universities/Institutes, H2 2016 51 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 52 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 53 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 54 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 55 Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 56 Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 57 Malaria - Pipeline by 4SC AG, H2 2016 58 Malaria - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 59 Malaria - Pipeline by Actelion Ltd, H2 2016 60 Malaria - Pipeline by Agilvax Inc, H2 2016 61 Malaria - Pipeline by Akshaya Bio Inc., H2 2016 62 Malaria - Pipeline by Allergy Therapeutics Plc, H2 2016 63 Malaria - Pipeline by Amura Holdings Limited, H2 2016 64 Malaria - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 65 Malaria - Pipeline by Artificial Cell Technologies, Inc., H2 2016 66 Malaria - Pipeline by AstraZeneca Plc, H2 2016 67 Malaria - Pipeline by Bharat Biotech International Limited, H2 2016 68 Malaria - Pipeline by Callaghan Innovation Research Ltd., H2 2016 69 Malaria - Pipeline by Carna Biosciences, Inc., H2 2016 70 Malaria - Pipeline by CEL-SCI Corporation, H2 2016 71 Malaria - Pipeline by Celgene Corporation, H2 2016 72 Malaria - Pipeline by Cellceutix Corporation, H2 2016 73 Malaria - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 74 Malaria - Pipeline by Cilian AG, H2 2016 75 Malaria - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 76 Malaria - Pipeline by DesignMedix, Inc., H2 2016 77 Malaria - Pipeline by Eisai Co., Ltd., H2 2016 78 Malaria - Pipeline by GenVec, Inc., H2 2016 79 Malaria - Pipeline by Genzyme Corporation, H2 2016 80 Malaria - Pipeline by GlaxoSmithKline Plc, H2 2016 81 Malaria - Pipeline by Hager Biosciences, LLC, H2 2016 82 Malaria - Pipeline by Horizon Pharma Plc, H2 2016 83 Malaria - Pipeline by iBio, Inc., H2 2016 84 Malaria - Pipeline by Imaxio SA, H2 2016 85 Malaria - Pipeline by Immtech Pharmaceuticals, Inc., H2 2016 86 Malaria - Pipeline by Immunovaccine Inc, H2 2016 87 Malaria - Pipeline by IPCA Laboratories Limited, H2 2016 88 Malaria - Pipeline by IRBM Science Park SpA, H2 2016 89 Malaria - Pipeline by Jenrin Discovery, Inc., H2 2016 90 Malaria - Pipeline by Jomaa Pharma GmbH, H2 2016 91 Malaria - Pipeline by Kancera AB, H2 2016 92 Malaria - Pipeline by Kymab Limited, H2 2016 93 Malaria - Pipeline by Lipocure Ltd., H2 2016 94 Malaria - Pipeline by Lipotek Pty Ltd., H2 2016 95 Malaria - Pipeline by LondonPharma Ltd, H2 2016 96 Malaria - Pipeline by Merck & Co., Inc., H2 2016 97 Malaria - Pipeline by Merck KGaA, H2 2016 98 Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2016 99 Malaria - Pipeline by Microbiotix, Inc., H2 2016 100 Malaria - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 101 Malaria - Pipeline by Mucosis B.V., H2 2016 102 Malaria - Pipeline by Mymetics Corporation, H2 2016 103 Malaria - Pipeline by Novartis AG, H2 2016 104 Malaria - Pipeline by PaxVax, Inc., H2 2016 105 Malaria - Pipeline by Pfenex Inc., H2 2016 106 Malaria - Pipeline by Pfizer Inc., H2 2016 107 Malaria - Pipeline by Protein Potential, LLC, H2 2016 108 Malaria - Pipeline by Rodos BioTarget GmbH, H2 2016 109 Malaria - Pipeline by Sanaria Inc., H2 2016 110 Malaria - Pipeline by Sanofi, H2 2016 111 Malaria - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 112 Malaria - Pipeline by Selecta Biosciences, Inc., H2 2016 113 Malaria - Pipeline by Sigma-Tau S.p.A., H2 2016 114 Malaria - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 115 Malaria - Pipeline by Telormedix SA, H2 2016 116 Malaria - Pipeline by Tomegavax, Inc., H2 2016 117 Malaria - Pipeline by VLP Biotech, Inc., H2 2016 118 Malaria - Pipeline by VLP Therapeutics, LLC, H2 2016 119 Malaria - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 120 Assessment by Monotherapy Products, H2 2016 121 Assessment by Combination Products, H2 2016 122 Number of Products by Stage and Target, H2 2016 124 Number of Products by Stage and Mechanism of Action, H2 2016 127 Number of Products by Stage and Route of Administration, H2 2016 130 Number of Products by Stage and Molecule Type, H2 2016 132 Malaria - Dormant Projects, H2 2016 384 Malaria - Dormant Projects (Contd..1), H2 2016 385 Malaria - Dormant Projects (Contd..2), H2 2016 386 Malaria - Dormant Projects (Contd..3), H2 2016 387 Malaria - Dormant Projects (Contd..4), H2 2016 388 Malaria - Dormant Projects (Contd..5), H2 2016 389 Malaria - Dormant Projects (Contd..6), H2 2016 390 Malaria - Dormant Projects (Contd..7), H2 2016 391 Malaria - Dormant Projects (Contd..8), H2 2016 392 Malaria - Dormant Projects (Contd..9), H2 2016 393 Malaria - Dormant Projects (Contd..10), H2 2016 394 Malaria - Dormant Projects (Contd..11), H2 2016 395 Malaria - Dormant Projects (Contd..12), H2 2016 396 Malaria - Discontinued Products, H2 2016 397 Malaria - Discontinued Products (Contd..1), H2 2016 398
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
